IovanceBiotherapeutics (IOVA) Downgradedby ZacksInvestmentResearch to Sell

IovanceBiotherapeutics} stock has undergone multiple analysts rating changes in the recent past.  IovanceBiotherapeutics Downgradedby ZacksInvestmentResearch on 10-08-21. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More IovanceBiotherapeutics (IOVA) Downgradedby ZacksInvestmentResearch to Sell